Last updated on May 2018

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa


Brief description of study

The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and aluminum-phosphate adjuvanted Clade C gp140 for the prevention of Human Immuno Virus (HIV) infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1 infections diagnosed between the Month 7 and Month 24 visits.

Clinical Study Identifier: NCT03060629

Contact Investigators or Research Sites near you

Start Over

Study Contact

MeCRU Clinical Research Unit
Pretoria, South Africa
0.88miles
  Connect »

Study Contact

Stanza Clinical Research Centre : Mamelodi
Mamelodi East, South Africa
2.28miles
  Connect »